Publicaciones en colaboración con investigadores/as de Dana–Farber Cancer Institute (9)

2023

  1. Generation of mouse models carrying B cell restricted single or multiplexed loss-of-function mutations through CRISPR-Cas9 gene editing

    STAR Protocols, Vol. 4, Núm. 4

  2. In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities

    Blood cancer discovery, Vol. 4, Núm. 2, pp. 150-169

  3. Loss-of-function lesions impact B-cell development and fitness but are insufficient to drive CLL in mouse models

    Blood Advances, Vol. 7, Núm. 16, pp. 4514-4517

2021

  1. Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression

    Blood Cancer Journal, Vol. 11, Núm. 7

2020

  1. CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition

    Leukemia, Vol. 34, Núm. 6, pp. 1599-1612

  2. Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications

    International Journal of Cancer, Vol. 147, Núm. 10, pp. 2780-2792

  3. High throughput single-cell detection of multiplex CRISPR-edited gene modifications

    Genome Biology, Vol. 21, Núm. 1

2019

  1. DNA damage response-related alterations define the genetic background of patients with chronic lymphocytic leukemia and chromosomal gains

    Experimental Hematology, Vol. 72, pp. 9-13

  2. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies

    Cancer Cell, Vol. 36, Núm. 4, pp. 369-384.e13